Skip to content
Screener

Dianthus Therapeutics DNTH Milestone — Revenue Recognition Milestone Method Pending

Similar metrics at other companies

Climb Bio, Inc. logo
CLYMSales Milestones — Milestone Payments
$8M—
Tarsus Pharmaceuticals, Inc. logo
TARSSales-based Milestones — Maximum milestone payments
$4M—
Tarsus Pharmaceuticals, Inc. logo
TARSClinical Milestones — Contractual milestone payment net sales
$500K—
Tarsus Pharmaceuticals, Inc. logo
TARSCommercial and Sales Milestones — Maximum milestone payments
$77M0.0%
Axsome Therapeutics logo
AXSMMilestone Revenue — Revenue
$500K—
Cytokinetics logo
CYTKDevelopment And Commercial Milestones — Maximum Milestone Additional Amount Receivable
$70M—

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$6.15B+838%
Enterprise value$5.52B+758%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0×0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept dnth:RevenueRecognitionMilestoneMethodPending.

The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001690585-26-000022

of certain clinical costs; (iii) development milestones totaling up to $15.0 million; and (iv) royalties on net sales ranging from the mid-single digits to the low teen percentages. Tenacia is also responsible for paying local development costs in Greater China and a portion of the central development costs based on the number of patients enrolled from China in our global Phase 3 studies.

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dianthus Therapeutics's milestone — revenue recognition milestone method pending?
Dianthus Therapeutics (DNTH) reported milestone — revenue recognition milestone method pending of $15M in Q1 2026.
How has Dianthus Therapeutics's milestone — revenue recognition milestone method pending changed year-over-year?
Dianthus Therapeutics's milestone — revenue recognition milestone method pending decreased by 0.0% year-over-year, from $15M to $15M.
What does milestone — revenue recognition milestone method pending mean?
This metric represents revenue associated with specific clinical or regulatory milestones that has not yet been recognized under the company's accounting policy. It reflects the value of contingent payments from collaborative partners that are awaiting the achievement of defined performance criteria or regulatory approval. Tracking this helps investors understand the potential future revenue pipeline tied to successful development outcomes.

Ask your AI about Dianthus Therapeutics's milestone — revenue recognition milestone method pending.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude